MedPath

Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

Not Applicable
Completed
Conditions
Hepatic Encephalopathy
Interventions
Registration Number
NCT01218568
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Brief Summary

The study will be double blind with respect to rifaximin, and randomization will be performed using tables of computer-generated random numbers. All subjects will be followed up till the recovery of HE (primary end point) or 10 days whichever is earlier. In the Lactulose group (group A) patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day along with placebo . In the lactulose plus rifaximin group (group B) patients will receive cap rifaximin 400mg three times a day along with lactulose. Primary endpoints will be recovery of overt HE patients who will not recover from HE after 10 days will be continued on the same treatment. Total duration of the study is 1 year.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Cirrhosis
  • Age 18-80
  • Hepatic encephalopathy grade II-IV
  • Informed consent
Exclusion Criteria
  1. Degenerative CNS disease or major psychiatric illness
  2. Serum creatinine > 1.5 mg/dl
  3. Active alcohol intake <4 weeks prior to present episode
  4. Others metabolic encephalopathies
  5. Hepatocellular Carcinoma
  6. Severe comorbidity such as CHF, Pulmonary disease, Neurological & Psychiatric problems impairing quality of life

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Rifaximin plus lactuloseRifaximin plus lactulose-
lactuloseLactulose30-60ml/day
Primary Outcome Measures
NameTimeMethod
Reversal of hepatic encephalopathy10 days
Secondary Outcome Measures
NameTimeMethod
Death10 days
duration of hospital stay10 days

Trial Locations

Locations (1)

Institute of Liver & Biliary Sciences (ILBS)

🇮🇳

New Delhi, Delhi, India

© Copyright 2025. All Rights Reserved by MedPath